scPharmaceuticals Elects Dorothy Coleman to Board of Directors and Appoints Brian Piekos as Chief Financial Officer
LEXINGTON, Mass., April 14, 2015 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that it has elected Dorothy A. Coleman to its board of directors and that it has appointed Brian Piekos as Chief Financial Officer.
Ms. Coleman, a 30-year veteran of the healthcare industry, is the Executive Vice President and Chief Financial Officer of The Lifetime Healthcare Companies, the parent corporation of Excellus BlueCross BlueShield in Rochester, New York. She previously held the same role at Blue Cross Blue Shield of Rhode Island and prior to that spent eight years with UnitedHealthcare in various executive leadership roles, including Chief Operating Officer of the Public Sector and CEO for the group's Southwest Ohio health plan. Prior to that, Coleman was CFO/COO of Cigna Healthcare Medical Group Practice of Arizona and CFO/Associate Administrator at FHP Inc. Hospital. She is a Certified Public Accountant and studied Finance at Arizona State University, holds a Bachelor of Science in Accounting from the University of Phoenix and is a 2016 MBA graduate of University of Rochester Simon Business School.
Mr. Piekos joined the company as its Chief Financial Officer and in this capacity will be responsible for the company's financial strategy and finance functions. Prior to his appointment, Mr. Piekos spent five years at Cubist Pharmaceuticals, Inc. most recently as the Senior Director of Corporate Finance, Tax and Treasury. Before joining Cubist, Mr. Piekos served as a Vice President of Investment Banking at Leerink Partners, formerly Leerink Swann, and Needham & Company where he was involved in numerous financing and strategic transactions in the biotechnology and healthcare industry. He began his career as a research associate at Millennium Pharmaceuticals and Biogen. Mr. Piekos holds an MBA from the University of Rochester Simon Business School, an MS from the University of Massachusetts Medical School and BA in Biochemistry from Ithaca College.
"scPharmaceuticals is honored and excited to welcome Ms. Coleman and Mr. Piekos at this important time in the company as we transition from research and non-clinical development activities to the start of pivotal studies, preparation for our first NDA filing and positioning the company for successful product introductions in 2016," said Pieter Muntendam, President, CEO and founder of scPharmaceuticals, and a member of its board of directors. "We stand to benefit tremendously from their knowledge and experience on changing medical paradigms to reduce the cost of care and in the process, create a strong and enduring company."
About scPharmaceuticals:
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs, go to www.scpharmaceuticals.com.
SOURCE scPharmaceuticals, Inc.
Share this article